Cell Therapy in a Crowded IO Landscape: Where Will Each Modality Have the Greatest Impact?

Session details:

As the IO landscape expands beyond traditional CAR-T, clinicians and developers are evaluating an increasingly diverse set of therapeutic approaches—from autologous and allogeneic CAR-Ts to TCR-T therapies, in vivo cell engineering, T-cell engagers, iPSC-derived therapies, and other engineered immune cell platforms. As these modalities mature, where will each ultimately fit within the treatment paradigm? This panel brings together leaders across the field to discuss the clinical data generating the most excitement, the challenges each approach must overcome, and where they see the greatest opportunity to improve patient outcomes. Discussion Points

• How will CAR-T, TCR-T, in vivo cell therapies, T-cell engagers, and emerging cell platforms coexist in future treatment paradigms?
• Which recent clinical data have most shifted expectations for each modality?
• What unmet needs remain best addressed by engineered cell therapies?
• Where are the biggest scientific, manufacturing, or clinical challenges still limiting broader adoption?
• Which platforms appear best positioned for solid tumors, earlier lines of therapy, or curative intent?